Characteristics of premanufacture CD8⁺T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.

ABSTRACT: Although chimeric antigen receptor (CAR) T cells have become an important treatment option for patients with relapsed/refractory B-cell malignancies, more than 60% of patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR-T cell therapies fail to achieve a durable response. To reveal changes in CAR-T cell therapy and identify response biomarkers, we conducted a retrospective analysis of pre-manufacture source T cells and CAR-T cell products and their association with outcome in 58 patients with r/rDLBCL who received tandem CD19/CD20 CAR-T cell therapy. We performed bulk RNA-Seq, single-cell RNA-Seq, and paired T cell receptor sequencing on CAR-T cell products and pre-manufacture T cells from DLBCL patients. We note that a CD8⁺ stem cell-like memory T cell populatio

SUBMITTER: Wang Y 

PROVIDER: S-EPMC10598004 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature